Drug Trial Radar · NCT07760922
Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,168
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Xinqiao Hospital of ChongqingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The First Affiliated Hospital of Nanchang University
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb/IIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference. TAMIS is a multicenter, randomized, double-blind, placebo-controlled superiority trial in patients with acute moderate ischemic stroke (NIHSS 4-10) within 24 hours of last known well. Eligible patients are randomized 1:1 to tirofiban plus aspirin versus placebo plus aspirin, both on a background of guideline-based standard medical care. The primary efficacy endpoint is the proportion of patients with an excellent functional outcome (mRS 0-1) at 90 days. The primary safety endpoint is symptomatic intracranial hemorrhage within 48 (±12) hours by the Heidelberg criteria.
Conditions
- Ischemic Stroke, Acute
Interventions
TirofibanDrug
Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban after randomization: 0.4 µg/kg/min for the first 30 minutes, then 0.1 µg/kg/min for a total of 24 hours. Plus guideline-based standard care.
Tirofiban-matching placeboDrug
Aspirin 100 mg once daily orally for 90 days, plus immediate intravenous tirofiban-matching placebo infusion (0.4 µg/kg/min × 30 min, then 0.1 µg/kg/min × 24 h). Plus guideline-based standard care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with mRS 0-1 at 90 days (%)Time frame: At 90 days after randomization
- Symptomatic intracranial hemorrhage within 48 (±12) hours (Heidelberg criteria) (%)Time frame: 48 (±12) hours after randomization
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
The First People's Hospital of Jingdezhen City
Jingdezhen, Jiangxi, China
The First People's Hospital of Jiujiang City
Jiujiang, Jiangxi, China
The First Affiliated Hospital of Gannan Medical University
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.